Efficacy of verum and sham acupoint catgut embedding for treatment of obesity: Study protocol for a randomized controlled trial
Autor: | Bing Yan, Hai-Bo Yu, Yumei Zhou, Zhuo-Xin Yang, Wei-Qu Yuan |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
Adult
Male medicine.medical_specialty China Waist Time Factors Adolescent Acupuncture Therapy Medicine (miscellaneous) Blood lipids 030204 cardiovascular system & hematology Body fat percentage law.invention 03 medical and health sciences Study Protocol Young Adult 0302 clinical medicine Randomized controlled trial Quality of life law Internal medicine Weight Loss medicine Humans Pharmacology (medical) 030212 general & internal medicine Acupoint catgut embedding Obesity Aged Randomized Controlled Trials as Topic Catgut lcsh:R5-920 business.industry Middle Aged medicine.disease Visceral fat area Clinical trial Treatment Outcome Female business lcsh:Medicine (General) Body mass index Acupuncture Points |
Zdroj: | Trials, Vol 20, Iss 1, Pp 1-9 (2019) Trials |
ISSN: | 1745-6215 |
Popis: | BackgroundObesity has become a major public health hazard with epidemic proportions, affecting adults, adolescents, and children of both genders. Previous studies have suggested that acupoint catgut embedding (ACE) might be a potential therapeutic approach for obesity. The purpose of this study is to conduct a rigorous and normative trial to determine the efficacy of ACE for obesity.Methods/designA total of 99 eligible patients diagnosed with obesity will be recruited in this study. They will be randomly allocated to either the verum ACE group, sham ACE group, or waiting list (WL) group, with 33 patients in each group. Each patient in the two ACE-based groups will receive eight sessions of treatment, lasting over 8 weeks. The primary outcome is the reduction of body mass index (BMI) after treatment. Secondary outcomes will include waist circumference (WC), hip circumference (HC), waist:hip ratio, body fat percentage, blood lipid level, subcutaneous fat area, visceral fat area, and World Health Organization Quality of Life (WHOQOL). All the outcomes will be evaluated at baseline, at the end of the 8 weeks of treatments, and at 3 months of follow-up. The evaluators and data analyzers will be blinded to group allocation.DiscussionThe findings of this randomized, sham-, and WL-controlled trial will help to investigate the influence of ACE on clinical variables as well as visceral fat area of obesity, which will provide high-quality evidence on the efficacy of ACE for obesity.Trial registrationChinese Clinical Trial Registry,ChiCTR1800020248. Registered on December 21, 2018. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |